Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Half of the global human population harbors the gastric bacterial pathogen He/icobacter pylori. This bacterium induces chronic gastritis that progresses through a histologic cascade and ultimately results in gastric cancer in 1- 3% of all those infected. In addition, 10-15% of infected individuals will develop peptic ulcer disease. Antibiotics do not uniformly eradicate the infection and resistance to the most commonly used antibiotics for H. pylori infection is a major health problem worldwide. Therefore, rational alternative therapies that can limit the infection and/or increase the eradication by antibiotics are needed. We have recently discovered that two compounds initially developed to inhibit enzymes of the mammalian reverse transsulfuration pathway (RTP), namely aminooxyacetic acid (AOAA) and propargylglycine (PAG), inhibit the growth of H. pylori in vitro. Of particular relevance, we have generated multiple H. pylori isolates from an ongoing clinical cohort, including a strain that we have found to be resistant to metronidazole, a common clinical problem. The cytotoxic effect of the RTP inhibitors also occurs in the antibiotic-resistant strain, increasing the potential importance of these compounds for future human studies. Using targeted and untargeted metabolomics, we found that cystathionine, a main metabolite of the H. pylori RTP (HpRTP), accumulates in H. pylori treated with AOAA or PAG, suggesting that these inhibitors can also target this metabolic pathway. Further, we found that stomach colonization and gastritis are inhibited when H. pylori-infected mice are treated with AOAA. Altogether, these data indicate that the HpRTP is essential for H. pylori survival in vitro and in the stomach and is therefore a rational therapeutic target. We hypothesize that commercially available molecules that inhibit the HpRTP result in bacterial killing and represent a novel treatment strategy to reduce H. pylori colonization and associated diseases. This entirely new concept for H. pylori treatment will be studied through two Specific Aims. 1) In vivo: To test if the compounds AOAA and PAG reduce H. pylori-induced diseases. A) We will determine colonization and gastritis in H. pylori-infected C57BL/6 mice treated or not with AOAA or PAG; we will also determine the mucosal immune response, the metabolomic signature of the gastric tissues, and the composition of the gastric microbiota. B) We will investigate the effect of these compounds on colonization, development and extension of dysplasia/carcinoma, and oncogenic signaling in dysplasia-prone FVB/N mice overexpressing the human gastrin gene (INS-GAS). C) The combination of antibiotic therapy with AOAA or PAG will be tested on antibiotic-susceptible and resistant clinical isolates. 2) In vitro: To delineate the molecular mechanisms by which AOAA and PAG affect H. pylori. A) We will use an approach combining metabolomics with classical microbiological and biochemical investigations to identify the enzyme(s) of the HpRTP inhibited by both compounds. B) We will determine whether AOAA/PAG influence the transcriptome of H. pylori, including the expression of the main virulence factors. Together, these studies are expected to provide new insights that can be translated to future investigations in humans with H. pylori infection, to limit infection burden and related diseases.
Grant Summary
Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $481K for university, nonprofit, healthcare org. Applications are due 2028-03-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $481K
2028-03-31
- 1Confirm your organization is eligible for Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection: Frequently Asked Questions
Who is eligible for the Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection?
Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection provide?
Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection provides up to $481K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection deadline?
Applications for Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection are due 2028-03-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection?
To apply for Inhibitors of the Reverse Transsulfuration Pathway as a New Treatment for Helicobacter pylori Infection, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.